Luo H, Wang T, Xiao L, Wang C, Yi H. Multiple disciplinary team management of rare primary splenic malignancy: Two case reports. World J Clin Cases 2022; 10(29): 10535-10542 [PMID: 36312480 DOI: 10.12998/wjcc.v10.i29.10535]
Corresponding Author of This Article
Tao Wang, MD, Surgeon, Department of General Surgery Center, General Hospital of Western Theater, No. 270 Rongdu Road, Chengdu 610083, Sichuan Province, China. wangtao301020@sina.com
Research Domain of This Article
Surgery
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2022; 10(29): 10535-10542 Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10535
Multiple disciplinary team management of rare primary splenic malignancy: Two case reports
Hao Luo, Tao Wang, Le Xiao, Chao Wang, Hai Yi
Hao Luo, Tao Wang, Le Xiao, Department of General Surgery Center, General Hospital of Western Theater, Chengdu 610083, Sichuan Province, China
Chao Wang, Department of Pathology, General Hospital of Western Theater, Chengdu 610083, Sichuan Province, China
Hai Yi, Department of Hematology, General Hospital of Western Theater, Chengdu 610083, Sichuan Province, China
Author contributions: Luo H and Wang T reviewed the literature and contributed to manuscript drafting; Xiao L was the follow-up physician; Wang C was the MDT member for pathology analysis and contributed to manuscript drafting; Yi H was the MDT member for hematology and contributed to manuscript drafting.
Supported bythe NSFC, No. 81502696; Technology Plan Program of Sichuan Province; No. 2018JY0185; Program of General Hospital of Western Theater, No. 2021-XZYG-C3; and Science & Technology Department of Sichuan Province International Cooperation Program, No. 2019YFH0056 and 2020YFSY0022.
Informed consent statement: Both patients included in this study provided signed informed consent.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Wang, MD, Surgeon, Department of General Surgery Center, General Hospital of Western Theater, No. 270 Rongdu Road, Chengdu 610083, Sichuan Province, China. wangtao301020@sina.com
Received: July 20, 2021 Peer-review started: July 20, 2021 First decision: October 16, 2021 Revised: November 27, 2021 Accepted: September 1, 2022 Article in press: September 1, 2022 Published online: October 16, 2022
Abstract
BACKGROUND
Malignant splenic tumors are rare but fatal, presenting a challenge in diagnosis and management involving hematology, oncology, and general surgery. By contrast, diagnosing and treating other common malignant tumors (such as lung and gastrointestinal cancer) offers multiple strategies for chemotherapy, radiotherapy, targeted therapy, and immunotherapy with the prospect of a cure. With various specialists involved in clinical multiple disciplinary team (MDT) discussion, personal bias can be minimized. It can also ignite important discussion which can benefit not only one patient but many patients.
CASE SUMMARY
Here, we report on the MDT diagnosis and management of the malignant splenic tumors littoral cell angiosarcoma and histiocytic sarcoma. Although only two cases of rare primary splenic malignancy are presented, MDT is a novel means of rare disease treatment.
CONCLUSION
To benefit patients, imaging analysis, safe operation, precise pathology examination, and individualized therapeutic treatment strategies are required. The involvement of various specialists in a clinical MDT discussion minimizes personal bias and can create important ideas to benefit all patients.
Core Tip: Malignant splenic tumors are rare but fatal, presenting a challenge in diagnosis and management. With various specialists involved in clinical multiple disciplinary team discussion, personal bias can be minimized. It can also ignite important discussion which can benefit not only one patient but many patients. In this article, we report the multiple disciplinary team (MDT) diagnosis and management of the malignant splenic tumors littoral cell angiosarcoma and histiocytic sarcoma. Although only two cases of rare primary splenic malignancy are presented, MDT is a novel means of rare disease treatment.
